Cost and reimbursement are also important variables to assess if the same formulary is used for the inpatient hospital and ambulatory clinics or satellite facilities . When a product is first approved , there is a lag time to availability for purchase . Biosimilar manufacturers may not be prepared for rapid uptake of their product , which may result in supply chain issues . There are several items that must be considered by a hospital P & T committee before adding a biosimilar product to formulary and these are discussed in detail later in this handbook .
Conclusions In the US , several barriers exist to implementation of biosimilars . Some may be remedied by education of providers and patients , while others are more difficult to overcome such as the regulatory hurdles and reimbursement issues . Many biosimilars are in the pipeline with the goal of further diversifying the biologic and biosimilar landscape . The US continues to learn how best to incorporate biosimilars into the health care system .
References 1 Mulcahy AW , Hlavka JP , Case SR . Biosimilar cost savings in the United States . RAND Health Quarterly 2018 ; 7 ( 4 ): 3 . 2 US Food and Drug Administration . Biosimilar Product Information .
www . fda . gov / drugs / therapeutic-biologicsapplications-bla / biosimilars ( accessed August 2020 ). 3 Rader RA . Biosimilars / Biobetters Pipeline Directory , online database . https :// www . biosimilardevelopment . com / doc / biosimilars-pipelineshows-remarkable-sustainedgrowth-0001 ( accessed August 2020 ). 4 Leonard E et al . Factors affecting health care provider knowledge and acceptance of biosimilar medicines : a systematic review . J Manag Care Spec Pharm 2019 ; 25 ( 1 ): 102 – 12 . 5 Barsell A , Rengifo-Pardo M , Erlich A . A survey assessment of U . S . dermatologists ’ perceptions of biosimilars . J Drugs Dermatol 2017 ; 16 ( 6 ): 612 – 15 . 6 Cohen H et al . Awareness , knowledge , and perceptions of biosimilars among specialty physicians . Adv Ther 2017 ; 33 ( 12 ): 2160 – 72 . 7 Gibofsky A , Badawi S . Biosimilar knowledge among U . S . rheumatologists – a survey [ abstract ]. Arthritis Rheumatol 2017 ; 69 ( Suppl 10 ). https :// acrabstracts . org / abstract / biosimilar-knowledge-amongus-rheumatologists-a-survey / ( accessed August 2020 ). 8 Trotta F et al . Impact of guidance on the prescription patterns of G-CSFs for the prevention of febrile neutropenia following anticancer chemotherapy : a populationbased utilization study in the Lazio region . BioDrugs 2017 ; 21 ( 2 ): 117 – 24 . 9 Nabhan C , Valley A , Feinberg BA . Barriers to oncology biosimilars uptake in the United States . Oncologist 2018 ; 23 ( 11 ): 1261 – 5 . 10 Pineles D et al . Patient perceptions regarding the use of biosimilars in inflammatory bowel disease . Am J Gastroenterol 2017 ; 112 : S418 – S419 . 11 Harvey RD et al . How will the cost of biosimilars affect patients ’ willingness to receive them ? J Clin Oncol 2019 ; 37:15-suppl , e18338-e18338 . 12 Heled Y . The case for disclosure of biologics manufacturing information . J Law Med Ethics 2019 ; 47 ( 4 _ suppl ): 54 – 78 . 13 US Department of Health and Human Services Food and Drug Administration , Center for Drug Evaluation and Research ( CDER ), and Center for Biologics Evaluation and Research ( CBER ). Guidance for industry reference product exclusivity for biological products filed under section 351 ( a ) of the PHS Act . www . fda . gov / media / 89049 / download ( accessed August 2020 ). 14 Dolan C . Opportunities and challenges in biosimilar uptake in oncology . Am J Manag Care 2018 ; 24 ( 11 Suppl ): S237 – S243 .
14 | 2021 | hospitalpharmacyeurope . com